Helix BioPharma Corp. (HBP.TO)
$0.22
-0.08 (-26.67%)
Rating:
Recommendation:
-
| Symbol | HBP.TO |
|---|---|
| Price | $0.22 |
| Beta | -0.039 |
| Volume Avg. | 0.03M |
| Market Cap | 38.356M |
| Shares () | - |
| 52 Week Range | 0.17-0.95 |
| 1y Target Est | - |
| DCF Unlevered | HBP.TO DCF -> | |
|---|---|---|
| DCF Levered | HBP.TO LDCF -> | |
| ROE | 313.52% | Strong Buy |
| ROA | -340.34% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -221.36% | Sell |
| P/E | - | |
| P/B | -16.84 | Strong Sell |
About
Download (Excel)Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.